Trial Profile
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs T-lymphocyte cell therapy (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors TC BioPharm
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 02 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.